These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Morena M; Cristol JP; Dantoine T; Carbonneau MA; Descomps B; Canaud B Nephrol Dial Transplant; 2000 Mar; 15(3):389-95. PubMed ID: 10692526 [TBL] [Abstract][Full Text] [Related]
23. Consequences of treatment with dexamethasone in rats on the susceptibility of total plasma and isolated lipoprotein fractions to copper oxidation. Belkebir-Mesbah D; Bonnefont-Rousselot D; Frey-Fressart V; Moinard C; Delattre J; Vasson MP Endocrine; 1999 Jun; 10(3):233-42. PubMed ID: 10484287 [TBL] [Abstract][Full Text] [Related]
25. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Evans M; Anderson RA; Graham J; Ellis GR; Morris K; Davies S; Jackson SK; Lewis MJ; Frenneaux MP; Rees A Circulation; 2000 Apr; 101(15):1773-9. PubMed ID: 10769276 [TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. Betteridge DJ; O'Bryan-Tear CG Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467 [TBL] [Abstract][Full Text] [Related]
27. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients. Beaudeux JL; Guillausseau PJ; Peynet J; Flourie F; Assayag M; Tielmans D; Warnet A; Rousselet F Clin Chim Acta; 1995 Aug; 239(2):131-41. PubMed ID: 8542651 [TBL] [Abstract][Full Text] [Related]
28. [Effects of plasma very low density lipoprotein, low density lipoprotein and high density lipoprotein on platelet aggregation in endogenous hypertriglyceridemia]. Deng Z; Liu B; Zhou J; Zhang Z; Liu Y; Bai H Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):704-7. PubMed ID: 14619587 [TBL] [Abstract][Full Text] [Related]
29. Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification. Ishikawa T; Suzukawa M; Ito T; Yoshida H; Ayaori M; Nishiwaki M; Yonemura A; Hara Y; Nakamura H Am J Clin Nutr; 1997 Aug; 66(2):261-6. PubMed ID: 9250103 [TBL] [Abstract][Full Text] [Related]
30. HDL capacity to inhibit LDL oxidation in well-trained triathletes. Brites F; Zago V; Verona J; Muzzio ML; Wikinski R; Schreier L Life Sci; 2006 May; 78(26):3074-81. PubMed ID: 16488445 [TBL] [Abstract][Full Text] [Related]
31. Banana prevents plasma oxidative stress in healthy individuals. Yin X; Quan J; Kanazawa T Plant Foods Hum Nutr; 2008 Jun; 63(2):71-6. PubMed ID: 18264767 [TBL] [Abstract][Full Text] [Related]
32. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537 [TBL] [Abstract][Full Text] [Related]
33. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Petit D; Bonnefis MT; Rey C; Infante R Atherosclerosis; 1988 Dec; 74(3):215-25. PubMed ID: 3240333 [TBL] [Abstract][Full Text] [Related]
34. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811 [TBL] [Abstract][Full Text] [Related]
36. Susceptibility of serum lipids to copper-induced peroxidation correlates with the level of high density lipoprotein cholesterol. Shimonov M; Pinchuk I; Bor A; Beigel I; Fainaru M; Rubin M; Lichtenberg D Lipids; 1999 Mar; 34(3):255-9. PubMed ID: 10230719 [TBL] [Abstract][Full Text] [Related]
37. Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. Córdoba-Porras A; Sánchez-Quesada JL; González-Sastre F; Ordóñez-Llanos J; Blanco-Vaca F J Mol Med (Berl); 1996 Dec; 74(12):771-6. PubMed ID: 8974018 [TBL] [Abstract][Full Text] [Related]
38. [Oxidation of low-density lipoproteins. Correlation between reduced resistance in vitro and increased oxidation in vivo]. Maggi E; Falaschi F; Perani G; Frattoni A; Finardi G; Bellomo G Presse Med; 1995 Mar; 24(9):431-6. PubMed ID: 7746815 [TBL] [Abstract][Full Text] [Related]
39. A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein. McDowell IF; McEneny J; Trimble ER Ann Clin Biochem; 1995 Mar; 32 ( Pt 2)():167-74. PubMed ID: 7785944 [TBL] [Abstract][Full Text] [Related]
40. Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients. Chen MF; Hsu HC; Lee YT Cardiovasc Drugs Ther; 1997 Dec; 11(6):787-93. PubMed ID: 9512874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]